Econ­o­mists, health pol­i­cy ex­perts say J&J's IRA ar­gu­ments are 'over­ly sim­plis­tic'

A group of econ­o­mists and health pol­i­cy ex­perts from some of the coun­try’s top uni­ver­si­ties has called John­son & John­son’s chal­lenge to the In­fla­tion Re­duc­tion Act “over­ly sim­plis­tic and mis­lead­ing” in a new court fil­ing.

J&J In­no­v­a­tive Med­i­cine, pre­vi­ous­ly known as Janssen, is one of sev­er­al phar­ma­ceu­ti­cal com­pa­nies su­ing the fed­er­al gov­ern­ment over what they claim are vi­o­la­tions of the Con­sti­tu­tion in the IRA’s Medicare ne­go­ti­a­tion pro­vi­sions. The gov­ern­ment is weeks away from propos­ing what it says should be the max­i­mum fair price for the 10 drugs se­lect­ed for the first round of ne­go­ti­a­tions. While man­u­fac­tur­ers will have a month to pro­pose a coun­terof­fer, many have ar­gued that the ne­go­ti­a­tions are more akin to price con­trols.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.